Monday, October 5, 2026

MatX and Neysa Raise $1.1B Combined as AI Hardware Funding Shifts Beyond NVIDIA

MatX raised $500M in Series B while Neysa secured $600M, both in February 2026, signaling investor confidence in specialized AI hardware infrastructure. The funding wave reflects growing demand for alternatives to NVIDIA's GPU dominance as workloads diversify across training, inference, and quantum-classical integration.

LM Salvado

March 14, 2026

MatX and Neysa Raise $1.1B Combined as AI Hardware Funding Shifts Beyond NVIDIA
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

MatX closed a $500 million Series B round in February 2026, while Neysa raised $600 million the same month, marking $1.1 billion in combined funding for AI hardware infrastructure companies outside NVIDIA's ecosystem.

The parallel raises indicate investors are betting on a diversified AI hardware stack by 2027. MatX focuses on specialized chips for AI training and inference optimization, while Neysa builds cloud compute infrastructure specifically for AI workloads.

The timing aligns with technical developments showing performance gains from hardware specialization. AMD's high-performance compute recently boosted PennyLane performance, demonstrating how quantum-classical computing integration requires purpose-built processors beyond standard GPUs.

Industry analysis suggests the AI accelerator market is expanding rather than fragmenting. "It's not a zero-sum game between CPUs and GPUs, because there's more and more workloads," according to market observers. CPUs are growing while GPUs maintain momentum as AI applications multiply.

NVIDIA still dominates AI hardware, supplying chips to Microsoft, Alphabet, and Amazon for their cloud AI services. However, the company faces increasing competition from AMD and emerging specialized chip makers.

The $1.1 billion funding surge tests a clear hypothesis: that AI hardware infrastructure is diversifying beyond GPU monopoly. Key metrics include the number of non-NVIDIA chip companies reaching production scale, market share shifts in AI accelerators, performance benchmarks comparing specialized chips to GPUs, and adoption rates by major cloud providers.

MatX and Neysa represent different approaches to the same opportunity. MatX builds custom silicon for specific AI operations, while Neysa optimizes cloud infrastructure around diverse hardware. Both strategies assume enterprises will demand alternatives to NVIDIA as AI workloads become more varied and cost-sensitive.

The February 2026 funding window suggests institutional investors see near-term revenue opportunities in AI hardware diversification, not just long-term potential. Production timelines for AI chips typically run 18-24 months, positioning these companies for 2027-2028 commercial deployment.

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com